The future of vitamin D analogs

Carlien Leyssens, Lieve Verlinden and Annemieke Verstuyf*

Clinical and Experimental Endocrinology, Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium

Edited by: Carsten Carlberg, University of Eastern Finland, Finland
Reviewed by: Ferdinand Molnár, University of Eastern Finland, Finland
Antonio Mourino, Universidad de Santiago, Spain
*Correspondence: Annemieke Verstuyf, Clinical and Experimental Endocrinology, Department of Clinical and Experimental Medicine, KU Leuven, Herestraat 49, bus 902, 3000 Leuven, Belgium e-mail: mieke.verstuyf@med.kuleuven.be

INTRODUCTION

The active form of vitamin D3, 1,25-dihydroxyvitamin D3 [1α,25(OH)2D3; 1 (Table 1)], is mostly known for its effects on bone, calcium, and phosphate homeostasis. Next to these classical effects, 1,25(OH)2D3 also exerts so-called non-classical effects on various tissues which express the vitamin D receptor (VDR) as well as the enzymes that are responsible for activating the hydroxylations of vitamin D3, which is essential for the formation of 1,25(OH)2D3. Thus, most tissues have the ability to convert vitamin D3 into its active form, 1,25(OH)2D3, which in turn will bind the VDR in order to positively or negatively influence target genes via binding of the 1,25(OH)2D3/VDR complex to vitamin D receptor elements (VDRE). Non-classical properties of 1,25(OH)2D3 include prodifferentiating and antiproliferative effects on normal and cancer cells (Colston et al., 1981; Jensen et al., 2001) as well as immunomodulatory effects. However, in order to obtain these non-classical effects, 1,25(OH)2D3 doses of the nanomolar range are necessary, while physiological 1,25(OH)2D3 serum concentrations are in the picomolar range. Since supraphysiological doses of 1,25(OH)2D3 result in hypercalcemia, 1,25(OH)2D3 analogs were developed to minimize the calcemic side effects while preserving or augmenting the beneficial effects of 1,25(OH)2D3. Both industry and academic institutions have synthesized a vast amount of vitamin D analogs. Some of these analogs have tissue-specific effects with low calcemic side effects and can be given at higher doses compared to the mother compound.

CLINICALLY APPROVED VITAMIN D ANALOGS

Given the huge amount of vitamin D analogs that have been synthesized during the years, it is nearly impossible to give an overview of them all. In the first part we will discuss vitamin D analogs that are clinically approved (Table 2). For several conditions such as secondary hyperparathyroidism, psoriasis and osteoporosis, vitamin D analogs are frequently used as a treatment option. Paricalcitol [2] and doxercalciferol [3] are vitamin D2 analogs approved for therapeutic use of secondary hyperparathyroidism. In Japan falecalcitriol [4] and maxacalcitol [5] are also used to treat this disease. Secondary hyperparathyroidism is characterized by elevated parathyroid hormone (PTH) levels in response to hypocalcemia and is often caused by chronic kidney disease. Above-mentioned vitamin D analogs suppress PTH, as does 1,25(OH)2D3, but without inducing severe hypercalcemia. Clinical studies with chronic kidney disease patients show that different analogs induce a stronger PTH suppression compared to placebo treatment (Hamdy et al., 1995; Coburn et al., 2004; Coyne et al., 2006). Also, end-stage renal disease patients treated with these analogs often have a better survival (Teng et al., 2003;
Table 1 | Overview of vitamin D analogs.

| Identification number | Name                                      | Structure |
|-----------------------|-------------------------------------------|-----------|
| [1]                   | 1α,25(OH)\(_2\)D\(_3\)                  | ![Structure](image1) |
| [2]                   | Paricalcitol (19-nor-1α,25(OH)\(_2\)D\(_2\)) | ![Structure](image2) |
| [3]                   | Doxercalciferol (1α(OH)D\(_2\))         | ![Structure](image3) |
| [4]                   | Falecalcitriol (26,27 F6-1α,25(OH)\(_2\)D\(_3\)) | ![Structure](image4) |
| [5]                   | Maxacalcitol (22oxa-1α,25(OH)\(_2\)D\(_3\)) | ![Structure](image5) |
| [6]                   | Tacalcitol (1α,24(R)(OH)\(_2\)D\(_3\))   | ![Structure](image6) |
| [7]                   | Calcipotriol (22-ene-26,27-dehydro-1α,25(OH)\(_2\)D\(_3\)) | ![Structure](image7) |
| [8]                   | Alfacalcidol (1α(OH)D\(_3\))            | ![Structure](image8) |
| [9]                   | Eldecalcidol (2β-(3-hydroxypropoxy)-1α,25(OH)\(_2\)D\(_3\)) | ![Structure](image9) |
| [10]                  | Seocalcitol (22,24-diene-24,26,27-trishomo-1α,25(OH)\(_2\)D\(_3\)) | ![Structure](image10) |
| [11]                  | 20-epi-1α,25(OH)\(_2\)D\(_3\)           | ![Structure](image11) |
| [12]                  | Lexicalcitol (20-epi-22-oxa-24,26,27-trishomo-1α,25(OH)\(_2\)D\(_3\)) | ![Structure](image12) |
| [13]                  | CD578 (17-methyl-19-nor-21-nor-23-yne-26,27-F6-1α,25(OH)\(_2\)D\(_3\)) | ![Structure](image13) |
| [14]                  | Inecalcitol (19-nor-14-epi-23-yne-1α,25(OH)\(_2\)D\(_3\)) | ![Structure](image14) |
Table 1 | Continued

| Identification number | Name | Structure |
|-----------------------|------|-----------|
| [15] TX527 | (19-nor-14,20-bisepi-23-yn-1α,25(OH)2D3) | ![TX527 structure](image) |
| [16] 2MD | (2-methylene-19-nor(20S)-1α,25(OH)2D3) | ![2MD structure](image) |
| [17] WY1112 | (Seco-C-9,11-bisnor-17-methyl-20-epi-26,27-F6-1α,25(OH)2D3) | ![WY1112 structure](image) |
| [18] PRI-2205 | (15E,7E-22-ene-26,27-dehydro-1α,25(OH)2D3) | ![PRI-2205 structure](image) |
| [19] ILX23-7553 | (16-ene-23-yn-1α,25(OH)2D3) | ![ILX23-7553 structure](image) |

Tentori et al., 2006; Shinaberger et al., 2008). However, few studies with chronic kidney disease and end-stage renal disease patients directly compare the effects of 1,25(OH)2D3 with its analogs. Psoriasis, a hyperproliferative condition of the skin, is also treated with vitamin D analogs. Tacalcitol [6], calcipotriol [7] and the recently approved eldecalcitol [9] is more effective than 1,25(OH)2D3 and alfalcaldiol [8] in increasing bone mineral density and mechanical strength in ovariectomized rats (Uchiyama et al., 2002). Various studies in mouse models as well as in patients show that treatment with eldecalcitol [9] leads to higher lumbar and hip bone mineral density and a lower incidence of new vertebral fractures (Ito et al., 2011; Matsumoto et al., 2011; Harada et al., 2012; Hagino et al., 2013), making eldecalcitol [9] a very promising new analog for the treatment of osteoporosis.

**GENOME- AND TRANSCRIPTOME-WIDE EFFECTS OF VITAMIN D ANALOGS**

The exact mechanism of action of vitamin D analogs still has to be deciphered. The reason why specific analogs have superagonistic actions on specific tissues remains unknown, however several studies have tried to elucidate the mechanisms behind these tissue-specific effects. The catabolism of vitamin D analogs is one of the mechanisms that have an effect on their potency. Modifications of the side chain of 1,25(OH)2D3 are known to slow down its catabolism by CYP24A1 (Jones, 1997). Seocalcitol (EB1089) [10] and 20-epi-1,25(OH)2D3 [11] are degraded slower compared to 1,25(OH)2D3 leading to a longer exposure of these analogs to the tissues (Hansen and Maenpaa, 1997; Kissmeyer et al., 1997; Shankar et al., 1997; Zella et al., 2009). The metabolites formed after catabolism of lexalcitodiol [12] are more active than the ones formed after 1,25(OH)2D3 is catabolized (Dilworth et al., 1997) and this analog is also more effective in slowing down the degradation rate of the VDR (van den Bemd et al., 1996). Moreover, since some cell types prefer specific catabolism pathways and enzymes above others, the degradation process may also contribute to the tissue-specific activity of vitamin D analogs. The affinity for the vitamin D binding protein (DBP) also plays a role in the activity of vitamin D analogs. Maxacalcitol [5] for example has a 500 times lower affinity for DBP and is thus cleared faster from the circulation than 1,25(OH)2D3 (Okano et al., 1989a). This analog has a short effect on bone and intestine, tissues responsible for calcium homeostasis, and a longer effect on PTH levels, making this analog ideal for the treatment of secondary hyperparathyroidism. However, it is still unknown why the duration of the effects is different in these tissues. Eldecalcitol [9] on the other hand has a higher DBP affinity compared to the mother compound, leading to longer sustained plasma levels and is thus more suitable for the treatment of osteoporosis (Okano et al., 1989b).

Another mechanism that contributes to the superagonistic effects of vitamin D analogs is their interaction with the VDR, co-activators and VDREs. 20-epi-1,25(OH)2D3, a C-20 epimer of 1,25(OH)2D3 [11], promotes heterodimerization between VDR and retinoid X receptor (RXR) (Liu et al., 2001). 20-epi-1,25(OH)2D3 [11] and other analogs like maxacalcitol [5], CD578 [13], inecalcitol [14], and TXS27 [15] require lower concentrations to recruit specific coactivators to the VDR/RXR/VDRE complex (Liu et al., 2000; Eelen et al., 2005, 2008; Schwinn and DeLuca, 2007). Approximately 10-fold lower doses of inecalcitol [14] and TXS27 [15] are needed, compared to 1,25(OH)2D3, to acquire the same amount of co-activator interactions (Eelen et al.,
Table 2 | Overview of clinically approved vitamin D analogs.

| Name                        | Structure | Indication                          | Brand name                        |
|-----------------------------|-----------|-------------------------------------|------------------------------------|
| Tacalcitol (1α,24(R)(OH)2D3) | ![Structure](image1.png) | Psoriasis                           | Curatoderm® (Almirall Hermal), Bonalfa® (ISDIN, Teijin Pharma),... |
| Paricalcitol (19-nor-1α,25(OH)2D3) | ![Structure](image2.png) | Secondary hyperparathyroidism       | Zemplar® (Abbott)                  |
| Doxercalciferol (1α(OH)D2)   | ![Structure](image3.png) | Secondary hyperparathyroidism       | Hectorol® (Genzyme corp)           |
| Falecalcitriol (26,27, F6-1α,25(OH)2D3) | ![Structure](image4.png) | Secondary hyperparathyroidism and psoriasis (Japan only) | Fulstan® (Dainippon Sumitomo) and Hornel® (Taisho Yakuhin) |
| Maxacalcitol (22oxa-1α,25(OH)2D3) | ![Structure](image5.png) | Secondary hyperparathyroidism       | Oxarol® (Chugai Pharmaceutical)    |
| Calcipotriol (22-ene-26,27-dehydro-1α,25(OH)2D3) | ![Structure](image6.png) | Psoriasis                           | Daivonex®, Dovonex® (LEO Pharmal, Sonlux® (Stiefel)) |
| Eldecalcitol (2β-(3-hydroxypropoxy)-1α,25(OH)2D3) | ![Structure](image7.png) | Osteoporosis (Japan only)           | Ediro® (Chugai Pharmaceutical)     |
Vitamin D analogs might also be able to induce tissue-specific effects by favoring binding to specific VDRE motifs in target gene promoters. Analogs with a 20-methyl group as well as seocalcitol [10] bound to a VDR/RXR complex preferably interact with the IP9 type of VDRE (Danielsson et al., 1996; Quack and Carlberg, 1999).

On the genome level, studies using chromatin immunoprecipitation (ChIP) and micro-array techniques have investigated 1,25(OH)2D3-regulated genes in different cell lines. One ChIP study compared the binding sites of VDR in intestinal tissue in the VDR gene located at 1,25(OH)2D3 or 20-epi-1,25(OH)2D3 [11] treatment. This study shows that both 1,25(OH)2D3 and 20-epi-1,25(OH)2D3 [11] induce VDR binding to CYP24AI and TRPV6 loci in the intestine, but the analog elicits a prolonged VDR binding to these genes leading to its superagonistic characteristics such as hypercalcemia in vivo (Zella et al., 2009). Other ChIP studies have tried to investigate the molecular mechanisms of some analogs in different tissues. In osteoblast cell models 2MD [16] bound to the VDR is able to bind VDREs at low concentrations compared to 1,25(OH)2D3 (Yamamoto et al., 2003). Seocalcitol [10], on the other hand, mediates the dissociation of Williams syndrome transcription factor of the aromatase promoter leading to inhibition of aromatase expression and activity in breast cancer cells which is one of the main therapeutic strategies in breast cancer patients (Lundqvist et al., 2013). In a recent paper binding sites of VDR and mothers against decapentaplegic homolog 3 (SMAD3) were investigated in hepatic stellar cells. These transforming growth factor β1 (TGFβ1)-activated cells play an important role in liver fibrosis. In this study it is shown that VDR and SMAD3 can at least transiently co-occupy the same genomic sites and function as enhancers of pro-fibrotic gene expression. However, when calcipotriol [7] is added, the TGFβ1-induced recruitment of SMAD3 is compromised and binding of VDR to these genomic sites is enhanced 10-fold meaning that liganded VDR antagonizes SMAD residency on chromatin and thereby suppresses pro-fibrotic gene expression (Ding et al., 2013). This genomic feedback circuit is a previously unknown mechanism of calcipotriol [7].

Micro-array studies in various cancer cell lines such as leukemia, prostate, breast, colorectal, and ovarian cancer show that a variety of gene clusters are influenced by 1,25(OH)2D3 and its analogs (reviewed in Kriebitzsch et al., 2009). Cell growth, apoptosis, cellular adhesion and extracellular matrix composition, oxidative stress, immune function, intra- and intercellular signaling and steroid/lipid metabolism are frequently modulated in these cells. The genomic changes associated with cardiac hypertrophy in the ventricular heart tissue of these rats are, in part, reversed by paricalcitol [2] administration (Bae et al., 2011). Furthermore, other studies investigated if 1,25(OH)2D3 analogs are able to bind and regulate different genes compared to 1,25(OH)2D3. All conducted studies conclude that 1,25(OH)2D3 and its analogs induce or repress the same set of genes. Seocalcitol [10] induces a less malignant phenotype in SCC25 squamous cell carcinoma cells and modulates expression of genes important in cell cycle progression, cell adhesion, extracellular matrix composition, intra- and intercellular signaling, G-protein coupled function, redox balance, and steroid metabolism. In these cells, seocalcitol [10] regulates the same genes compared to 1,25(OH)2D3, however gene regulation by 1,25(OH)2D3 is more transient (Lin et al., 2002). Also WY1112, a sec0-9,11-bisnor-17-methyl analog lacking the C-ring and with a 21-epi side chain which is fluorinated on C26 and C27 [17], was investigated in MCF-7 breast cancer cells. Despite the 400-fold stronger antiproliferative capacity of WY1112 [17], the same genes are upregulated after 1,25(OH)2D3 or WY1112 [17] treatment. However, the induction ability is much higher for the analog (Vanoirbeek et al., 2009). When treating human coronary artery smooth muscle cells with equal amounts of 1,25(OH)2D3 or paricalcitol [2] the same genes are regulated (Wu-Wong et al., 2007; Shalhoub et al., 2010). In conclusion, differences in action and capacity of vitamin D analogs are more due to their specific sensitivities to metabolism and their specific interaction with the VDR, co-activators and VDREs than from different gene regulations. However, to our knowledge no studies have yet looked into the potential differences elicited by analogs compared to 1,25(OH)2D3 in the fields of proteomics and epigenetics, which could help to understand the molecular mechanism of 1,25(OH)2D3 and its analogs on different cell and tissue types.

**EFFECTS OF VITAMIN D ANALOGS IN CANCER**

The use of 1,25(OH)2D3 for the treatment of cancer gained interest since many tissues express vitamin D metabolizing enzymes as well as the VDR and because 1,25(OH)2D3 has potent antiproliferative and prodifferentiating effects on normal and malignant cell lines. Several analogs evaluated in vitro show stronger antiproliferative and prodifferentiating effects compared to the mother compound in different cancer cell lines. These compounds are further evaluated in rodent models to assess their anti-cancer activity and safety in vivo. All in vivo studies using rodent cancer models that were published between 2007 and 2013 are summarized in Table 3. For studies preceding 2007, the reader is referred to other reviews (Eelen et al., 2007). In most studies the growth of the tumor is inhibited without inducing severe hypercalcemia when appropriate doses of vitamin D analogs are used (Abe et al., 1991; Kawa et al., 1996, 2005; Akhter et al., 1997, Blutt et al., 2000; Prudencio et al., 2001; Grostern et al., 2002; Flanagan et al., 2003; Albert et al., 2004a; Wietrzyk et al., 2004; Zhang et al., 2005; Fichera et al., 2007; van Ginkel et al., 2007; G hous et al., 2008; Lee et al., 2008; Schwartz et al., 2008; Gonzalez-Pardo et al., 2010; Seubwai et al., 2010; Berkovich et al., 2013;
### Table 3 | In vivo studies in rodent cancer models treated with vitamin D analogs (intraperitoneal i.p.; subcutaneous s.c.) published between 2007 and 2013.

| Cancer type                          | Dosage vitamin D analog                                                                 | Duration of treatment | Outcome                                                                 | References                  |
|--------------------------------------|----------------------------------------------------------------------------------------|-----------------------|------------------------------------------------------------------------|-----------------------------|
| Chemically-induced breast cancer     | 7 μg/kg/week                                                                           | Approximately 80 days | Decreased tumor burden and volume                                       | Liska et al., 2012          |
| Chemically-induced breast cancer     | Oral, 7 μg/kg/week                                                                     | 116 or 156 days       | Prolonged latency of mammary gland tumors                               | Macejova et al., 2011       |
| Prostate cancer xenograft            | i.p., 0.5 μg/kg every other day                                                        | 45 days               | Reversal of growth stimulatory effects of PTHrP                        | Bhatia et al., 2009         |
| Hepatocellular carcinoma xenograft   | Oral and i.p., 0.02/0.1/0.5 μg/kg/d                                                   | Approximately 21 days | Inhibition of tumor growth                                              | Ghous et al., 2008          |
| Inoculation with mice breast cancer  | i.p., 20 ng 3×/week                                                                    | 6 weeks               | Inhibition of tumor growth, no inhibition of tumor angiogenesis         | Valrance et al., 2007       |
| HY-11 (2-amino-3-deoxy-19-nor-22-ene-26-dihomo-27-dihomo-25(OH)D3) |                                                                                         |                       |                                                                         |                             |
| Inoculation with mice leukemia cells | i.p., 10^{-5} M/d                                                                       | 26 days               | 50% increase in survival                                                | Yoon et al., 2008           |
| Tacalcitol (1α,24(R)(OH)2D3)          |                                                                                         |                       |                                                                         |                             |
| Inoculation with mice colorectal cancer cells | Different concentrations s.c. (3 or 5×/week) or oral  (3×/week) in combination with different concentrations of 5-fluorouracil | Variable duration    | 1 μg/kg/d optimal dose + prolongation of life span of mice (synergistic effect when combined with chemotherapy) | Milczarek et al., 2013a     |
| Inoculation with mice or human colorectal cancer cells | s.c., Different concentrations in combination with different concentrations of irinotecan or oxaliplatin | Variable duration     | Under certain experimental conditions vitamin D analogs and chemotherapy can work synergistically | Milczarek et al., 2013b     |
| Cancer type                  | Dosage vitamin D analog | Duration of treatment | Outcome                                                                 | References          |
|-----------------------------|-------------------------|-----------------------|-------------------------------------------------------------------------|---------------------|
| Squamous cell carcinoma     | i.p., 80/160/320 μg/mouse/d | 3 days               | Inhibition of tumor growth, increased apoptosis, decreased proliferation | Ma et al., 2013     |
| Prostate cancer xenograft   | i.p., 1300 μg/kg 3×/week | 42 days               | Delay of tumor growth, 50% decrease in tumor weight and decreased tumor vascularity | Okamoto et al., 2012 |
| Kaposi sarcoma xenograft    | i.p., 10 μg/kg/d        | 4 days                | Decreased tumor progression                                             | Gonzalez-Pardo et al., 2010 |
| Gastric cancer xenograft    | s.c., 100 ng/d 3×/week  | 4 weeks               | Lower tumor volume, reduced growth of intraperitoneal metastasis         | Park et al., 2012   |
| Pancreatic cancer xenograft | s.c., 2.5 μg/kg 3×/week | Variable duration     | Inhibition of tumor growth                                              | Schwartz et al., 2008 |
| Neuroblastoma xenograft     | Oral, 0.15/0.3 μg/d     | 5 weeks               | Lower tumor volume                                                      | van Ginkel et al., 2007 |
Table 3 | Continued

| Cancer type                          | Dosage vitamin D analog | Duration of treatment | Outcome                                      | References               |
|--------------------------------------|-------------------------|-----------------------|----------------------------------------------|--------------------------|
| Cholangiocarcinoma xenograft         | i.p., 15 μg/kg/d        | 17 days               | Inhibition of tumor growth                   | Seubwai et al., 2010     |
| Maxacalcitol (22oxa-1α,25(OH)2D3)    |                         |                       |                                              |                          |
| UV-induced non-melanoma skin cancer  | Topical application in  | 17 weeks              | Decrease in number and area of tumors when combined with diclofenac | Pommergaard et al., 2013 |
| Calcipotriol (22-ene-26,27-dehydro-1α,25(OH)2D3) |                         |                       |                                              |                          |
| BGP-13 (1R, 3S, 5Z)-5-((8E)-2-((3R)-3-((2R, 3S)-3-(5-cyclopropyl-3H-1,2-dioxol-3-yl)-2-ethyl-3-methylcyclohexylidene)ethylidene)-4-methylenecyclohexane-1,3-diol) |                         |                       |                                              |                          |
| Colorectal cancer xenograft          | i.p., 2 μg/kg every 2 days | 8 days               | Inhibition of tumor growth                   | Berkovich et al., 2013   |
| PRI-2205 ((5E,7E)-22-ene-26,27-dehydro-1α,25(OH)2D3) |                         |                       |                                              | Wietrzyk et al., 2007    |
| Breast and lung cancer xenograft     | s.c., 10 μg/kg 2 or 3 x/week + cytostatics | 18-21 days | Combination of analogs with low doses of cytostatics is not effective |                          |
| Cancer type | Dosage vitamin D analog | Duration of treatment | Outcome | References |
|-------------|------------------------|-----------------------|---------|------------|
| **PRI-1906 ([(24E)-(1S)-24-dehydro-24α-homo-1α,25(OH)₂D₃])** | Inoculation with mice breast cancer cells | s.c., 0.1 or 1 μg/kg/d | 9 or 11 days | No effects | Wietrzyk et al., 2008 |
| **BXL-01-0126 (20R-(4-hydroxy-4-methylpentyl)-23-yne-23,27-hexafluoro-1α,25(OH)₂D₃)*** | Acute myeloid leukemia xenograft | i.p., 0.0625 μg | 1 injection | Cathelicidin antimicrobial peptide present in systemic circulation | Okamoto et al., 2014 |
| **BXL0124 (20R-21(3-hydroxy-3-deuteromethyl-4,4,4-trideuterobutyl)-23-yne-26,27-hexafluoro-1α,25(OH)₂D₃)*** | Breast cancer xenograft | i.p., 0.1 μg/kg or oral 0.03/0.1 μg/kg 6 days/week | 5 weeks | Suppressed tumor growth | So et al., 2011 |
| | Transgenic mice with breast cancer (ErbB2/Her-2/neu overexpressing tumors) | i.p., 0.3 μg/kg 3 x/week | Approximately 38 weeks | Inhibition of tumor growth and regulation of ErbB2/AKT/ERK pathway | Lee et al., 2010 |
| **Gemini0097 (20R-21(3-deuteromethyl-3-hydroxy-4,4,4-trideuterobutyl)-23-yne-26,27-hexafluoro-1α,25(OH)₂D₃)*** | ER-negative breast cancer xenograft | i.p., 0.1 μg/kg/d | 9 weeks | Suppressed tumor growth | Lee et al., 2008 |
| | Chemically-induced breast cancer (ER positive) | i.p., 0.03/0.1/0.3 μg/kg 5days/week | 9 weeks | Inhibition of tumor burden | |

(Continued)
### Table 3 | Continued

| Cancer type                      | Dosage vitamin D analog | Duration of treatment | Outcome                                  | References              |
|----------------------------------|-------------------------|-----------------------|------------------------------------------|-------------------------|
| MART-10 (19-nor-2α-(3-hydroxypropyl)-1α,25(OH)2D3) | i.p., 0.3 μg/kg 2×/week | 3 weeks               | Inhibition of tumor growth               | Chiang et al., 2013     |
| 1α,25(OH)2D3-3-bromoacetate      | i.p., 0.75 μg/kg every third day | 80 days             | Reduced tumor size and increased apoptosis | Lambert et al., 2010    |
| Ro26-2198 (16,23Z-diene-26,27-F6-19-nor-1α,25(OH)2D3) | 0.01 μg/kg/d via mini-osmotic pump | 28 days             | Inhibition of dysplasia progression and inhibition of proliferation and pro-inflammatory signals | Fichera et al., 2007    |

For studies preceding 2007 the reader is referred to other reviews (Eelen et al., 2007).

Chiang et al., 2013). However, in some models the analog dose that is effective in inhibiting tumor growth also causes hypercalcemia and lower survival of the treated animals (Albert et al., 2004b). Not only tumor proliferation is modulated by vitamin D analogs, also apoptosis, angiogenesis, migration of tumor cells, etc. are affected by some analogs. In xenograft studies where apoptosis in the tumor was investigated after vitamin D analog treatment, apoptosis or the necrotic field in the tumor is augmented (James et al., 1998; VanWeelden et al., 1998; Hara et al., 2001; Vegesna et al., 2003; Lambert et al., 2010; Park et al., 2012). Inecalcitol (Hybrigenics, France) [14] treatment of mice with squamous cell carcinoma xenografts increases apoptosis in the tumors and this increase is higher for the analog compared to 1,25(OH)2D3, while the capacity of the analog to inhibit proliferation is equal compared to the mother compound (Ma et al., 2013). Most studies agree that vitamin D analogs also have an effect on tumor metastasis. Seocalcitol [10] reverses the growth-stimulatory effects of parathyroid hormone-related protein (PTHrP), which plays a major role in prostate cancer progression and metastasis, in a xenograft mouse model of prostate cancer. The same study shows that seocalcitol [10] also inhibits migration and invasion of these prostate cancer cells in vitro (Bhatia et al., 2009). This analog also reduces the number and surface area of bone metastasis originating from intracardially injected breast cancer cells (El Abdaimi et al., 2000). Vitamin D analogs are thus able to reduce the number and growth of metastasis originating from various types of cancer cells (Sato et al., 1984; Lokeshwar et al., 1999; Nakagawa et al., 2005; Park et al., 2012). However, in a study using mice with chemically induced breast cancer, the invasion capacity of the tumor after seocalcitol [10] treatment is not affected (Liska et al., 2012). The effect of vitamin D analogs on angiogenesis has also been studied in vivo,
but here the results are more conflicting. Some studies show no effect of vitamin D analogs on angiogenesis (Oades et al., 2002; Valrance et al., 2007), while others find decreased angiogenesis of xenograft tumors. Intraperitoneal injections of inecalcitol [14] decrease the vascularity of xenograft prostate cancer cells (Okamoto et al., 2012) and oral treatment of colorectal tumors in rats with alfacalcidol [8] also inhibits tumor angiogenesis (Iseki et al., 1999). All in vivo studies conclude that vitamin D analogs inhibit tumor growth but vitamin D and its analogs often do not influence tumor number. Seocalcitol [10] was given as chemoprevention in a transgenic mouse model for androgen-independent prostate cancer. Tumor growth is inhibited, however, there is no prevention in the development of tumors (Perez-Stable et al., 2002).

Since vitamin D and its analogs do not possess cytostatic properties, many in vivo studies have focused on vitamin D analog cancer treatment combined with radiotherapy and/or chemotherapy. When seocalcitol [10] is combined with radiotherapy in a xenograft model for breast cancer, the anti-cancer effects are more effective compared to monotherapy (Sundaram et al., 2003). Another analog, tacalcitol [6], has been investigated in colorectal cancer xenograft in combination with different standard chemotherapies. Different concentrations as well as administration routes of tacalcitol [6] or PRI-2205 (an analog of calcipotriol) [18] were used in combination with different concentrations of 5-fluorouracil (5-FU). Using specific analog doses and chemotherapy schedules, a synergetic effect on the prolongation of the life span of the mice is achieved (Milczarek et al., 2013a). The combination with irinotecan or oxaliplatin was investigated. In this study the mice also show a longer life span and a stronger tumor growth inhibition compared to monotherapy when certain doses of tacalcitol [6] and chemotherapy were used. However, some combinations were more toxic than the monotherapies (Milczarek et al., 2013b). Other studies report better effects when combining calcipotriol [7] and diclofenac in a non-melanoma skin cancer model (Pommergaard et al., 2013). However, the combination of vitamin D analogs with chemotherapy does not always result in additive or synergistic effects. Combining maxacalcitol [5] and 5-FU did not enhance anti-tumor effects in a chemically induced breast cancer model (Iino et al., 1992). Another study investigated calcipotriol [7] and its derivatives in breast and lung cancer in vivo models and concluded that these analogs and low dose cytostatics are not effective in the used models (Wietrzyk et al., 2007). Also tacalcitol [6] in combination with cyclophosphamide does not lead to a significant difference in tumor growth inhibition compared to the vehicle treatment (Wietrzyk et al., 2008).

In view of the promising results that certain vitamin D analogs show against cancer in vitro and in vivo animal models, some analogs have been tested in cancer patients (Table 4). Seocalcitol [10] is an analog that has been extensively studied in vitro and in vivo in different cancer models, however in clinical trials the results are rather disappointing. Patients with advanced breast or colon cancer were treated with different doses of seocalcitol [10] (most patients tolerate 7 μg/d) but none of them showed a complete or partial response (Gulliford et al., 1998). Also oral seocalcitol [10] treatment in patients with inoperable pancreatic cancer exhibited no objective anti-tumor activity (Evans et al., 2002). Two out of 33 patients with inoperable hepatocellular carcinoma showed a complete response after oral seocalcitol [10] treatment, however the majority of the patients presented stable or progressive disease (Dalhoff et al., 2003). Inecalcitol [14] is in an early stage II of its clinical trial in chronic lymphocytic leukemia. Fifteen patients received 2 mg/d orally and one patient had a 90% decrease in blood lymphocyte count after 10 months of treatment, in 8 other patients blood lymphocyte count stopped growing when the treatment started (Hybrigenics, 2014). Intravenous administration of paricalcitol [2], an analog that is approved for secondary hyperparathyroidism, also displayed no objective responses in patients with androgen-independent prostate cancer. However, elevated serum PTH levels, which are common for advanced prostate cancers, are reduced by the analog (Schwartz et al., 2005). Doxercalciferol [3], also used in the treatment against secondary hyperparathyroidism, was investigated in androgen-independent prostate cancer patients. A phase I study administered oral doxercalciferol [3] between 5 and 15 μg/d, which was well tolerated by the patients (Liu et al., 2002). In the following phase II study, patients were treated with 12.5 μg/d for a minimum of 8 weeks and 30% of these patients experienced stable disease for over 6 months (Liu et al., 2003). Oral treatment of non-Hodgkin’s lymphoma patients with 1 μg/d alfacalcidol [8], a pre-metabolite of 1,25(OH)2D3, resulted in a low overall response. Out of 34 treated patients, only 4 had a complete response and 4 others showed a partial response to the treatment (Raina et al., 1991). Calcipotriol [7] is often used to treat skin psoriasis and has thus been investigated in patients with locally advanced or cutaneous metastases from breast cancer. In both studies the analog was applied topically at a dose of 100 μg/d. One study reported no response after 3 months of treatment (O’Brien et al., 1993), while in the other study 3 patients showed a 50% reduction in the diameter of treated lesions after 6 weeks (Bower et al., 1991). A more recently developed analog, ILX23-7553 [19], was investigated in 16 patients with advanced solid tumors but no objective response was seen (Jain et al., 2011). Similar to the in vivo studies, clinical trials have also combined vitamin D analogs with standard radiotherapy or chemotherapy. Metastatic breast cancer patients were given oral paricalcitol [2] doses between 2 and 7 μg/d in combination with taxane-based chemotherapy and this regimen was well tolerated by the patients (Lawrence et al., 2013). Oral inecalcitol [14] was given to patients with hormone-refractory prostate cancer in combination with docetaxel for maximum 18 weeks. This study had a response rate of 85% based on a PSA decline of at least 30% within 3 months of treatment (Hybrigenics, 2014). In a small study with acute non-lymphoid leukemia patients the combination of alfacalcidol [8] and chemotherapy resulted in 17% of the patients with a complete response and 45% with a partial response (Petrini et al., 1991). The same analog was combined with standard treatment of surgery, radiotherapy, and/or chemotherapy in glioblastoma and anaplastic astrocytomas. Here, 0.04 μg/kg/d alfacalcidol [8] was administered resulting in 27% of the patients with progressive regression of the lesion and complete clinical remission (Trouillas et al., 2001). In metastatic renal cell carcinoma patients, oral treatment of 1 μg alfacalcidol/d [8]
| Cancer type                                      | Sample size | Dosage vitamin D analog | Duration of treatment | Outcome                                                                 | References                          |
|------------------------------------------------|-------------|--------------------------|-----------------------|-------------------------------------------------------------------------|-------------------------------------|
| **Seocalcitol (22,24-diene-24,26,27-trishomo-1α,25(OH)₂D₃)** |             |                          |                       |                                                                         |                                     |
| Inoperable hepatocellular carcinoma            | 33          | Oral individual dosage, most patients tolerate 10 μg/d | Up to 1 year          | 2 patients with complete response; 12 with stable disease; 19 with progressive disease | Dalhoff et al., 2003 (uncontrolled trial) |
| Inoperable pancreatic cancer                   | 36          | Oral individual dosage, most patients tolerate 10–15 μg/d | Minimum 8 weeks       | No objective anti-tumor activity                                        | Evans et al., 2002 (uncontrolled trial) |
| Advanced breast cancer and colorectal cancer  | 36          | Individual dosage (solution), most patients tolerate 7 μg/d | From 5 days up to 1 year | No complete or partial responses                                        | Gulliford et al., 1998 (uncontrolled trial) |
| **Inecalcitol (19-nor-14-epi-23-yne-1α,25(OH)₂D₃)** |             |                          |                       |                                                                         |                                     |
| Hormone-refractory prostate cancer             | 54          | Oral individual dosage, maximum tolerated dose is 4 mg/d + docetaxel (chemotherapy) | Maximum 18 weeks      | 85% response rate based on a PSA decline of at least 30% within 3 months | Hybrigenics, 2014 (uncontrolled trial) |
| Chronic lymphocytic leukemia                   | 15          | Oral 2 mg/d              | Not found             | 1 patient had a 90% decrease in blood lymphocyte count after 10 months of treatment; in 8 patients blood lymphocyte count stopped increasing when treatment was started; 6 patients showed no response | Hybrigenics, 2014 (uncontrolled trial) |
| **Paricalcitol (19-nor-1α,25(OH)₂D₂)**         |             |                          |                       |                                                                         |                                     |
| Metastatic breast cancer                       | 24          | Oral individual dosage, 2–7 μg/d + taxane-based chemotherapy | 8 weeks               | Well tolerated regimen                                                 | Lawrence et al., 2013 (uncontrolled) |

(Continued)
| Cancer type                          | Sample size | Dosage vitamin D analog | Duration of treatment | Outcome                                      | References                                      |
|-------------------------------------|-------------|-------------------------|-----------------------|----------------------------------------------|------------------------------------------------|
| Androgen-independent prostate cancer | 18          | i.v., Individual dosage, 3×/week 5–25 μg | Up to 12 weeks       | No objective response, reduced serum PTH levels | Schwartz et al., 2005 (uncontrolled)            |
|                                     |             |                         |                       |                                              |                                                 |
| Localized prostate cancer and high grade prostatic intraepithelial neoplasia | 31          | Oral, 10 μg/d           | 4 weeks               | No beneficial effects in serum and tissue markers | Gee et al., 2013 (placebo-controlled)          |
|                                     |             |                         |                       |                                              |                                                 |
| Metastatic androgen-independent prostate cancer | 70          | Oral, 10 μg/d + docetaxel | 4 weeks               | No enhanced PSA response rate or survival   | Attia et al., 2008 (placebo-controlled)        |
|                                     |             |                         |                       |                                              |                                                 |
| Advanced androgen-independent prostate cancer | 26          | Oral, 12.5 μg/d        | Minimum 8 weeks       | 30% experienced stable disease for over 6 months | Liu et al., 2003 (uncontrolled)                |
|                                     |             |                         |                       |                                              |                                                 |
| Advanced androgen-independent prostate cancer | 25          | Oral individual dosage, 5–15 μg/d | Minimum 8 weeks       | Well tolerated, maximal tolerated dose was not reached | Liu et al., 2002 (uncontrolled)                |
|                                     |             |                         |                       |                                              |                                                 |
| Metastatic renal cell carcinoma     | 16          | Oral, 1 μg/d + interferon-α (3×/week) | Minimum 3 months      | 25% had partial response                     | Obara et al., 2008 (uncontrolled)             |
|                                     |             |                         |                       |                                              |                                                 |
| Glioblastoma and anaplastic astrocytomas | 11          | 0.04 μg/kg/d + surgery/chemotherapy/radiotherapy | Not found             | 27% showed progressive regression of the lesion and had a complete clinical remission | Trouillas et al., 2001 (uncontrolled)          |
|                                     |             |                         |                       |                                              |                                                 |
| Myelodysplastic syndromes           | 30          | Oral, 4–6 μg/d         | Median 17 months      | Prolongation of leukemic transformation-free survival | Motomura et al., 1991 (placebo-controlled)   |
|                                     |             |                         |                       |                                              |                                                 |
| Acute non-lymphoid leukemia         | 11          | Analog + chemotherapy   | Not found             | 17% complete remission, 45% partial remission | Petrini et al., 1991 (uncontrolled)          |
|                                     |             |                         |                       |                                              |                                                 |
| Progressive low-grade non-Hodgkin's lymphoma | 34          | Oral, 1 μg/d          | Minimum 8 weeks       | 4 patients has a complete response, 4 other patients had a partial response | Raina et al., 1991 (uncontrolled)            |
## Table 4 | Continued

| Cancer type | Sample size | Dosage vitamin D analog | Duration of treatment | Outcome | References |
|-------------|-------------|-------------------------|-----------------------|---------|------------|
| Locally advanced or cutaneous metastatic breast cancer | 19 | Topical 100 μg/d | 6 weeks | 3 patients showed 50% reduction in diameter of treated lesions | Bower et al., 1991 (uncontrolled) |
| Locally advanced or cutaneous metastatic breast cancer | 15 | Topical 100 μg/d | 3 months | No response | O’Brien et al., 1993 (uncontrolled) |
| Advanced solid tumors | 16 | Oral individual dosage, 1.7–37.3 μg/m²/d for 3 consecutive days, repeated in 7-day cycle | Minimum 3 weeks | No objective response | Jain et al., 2011 (uncontrolled) |

was combined with a 3 weekly administration of interferon-α for minimal 3 months. In these patients 25% had a partial response to the combination therapy (Obara et al., 2008). Randomized, placebo-controlled studies have been conducted with oral doxercalciferol [3] or alfacalcidol [8]. One study administered 10 μg/d doxercalciferol [3] or placebo during 4 weeks to patients with localized prostate cancer or high-grade prostatic intraepithelial neoplasia. However, no beneficial effects in serum or tissue markers were seen (Gee et al., 2013). Another study used the same dose in metastatic androgen-independent prostate cancer patients but combined the treatment with docetaxel. Also here, no enhanced PSA response rate or survival rate was seen after 4 weeks of treatment (Attia et al., 2008). Oral alfacalcidol [8] or placebo was given to patients with myelodysplastic syndromes. In the patients treated with the analog, a prolongation of leukemic transformation-free survival was seen compared to the placebo group (Motoamura et al., 1991). Despite the promising in vitro and in vivo results of vitamin D analogs in cancer models, clinical trials have failed to prove the effects of vitamin D analogs in cancer patients. Vitamin D and its analogs lack cytotoxic activity, so using these analogs in combination with standard therapies such as radio- and chemotherapy is probably more effective than using the analogs as monotherapy. Next to the combination of analogs with standard cancer therapies, it is also possible that these analogs need to be given for a longer period of time or that treatment with analogs has to be started earlier, for example in early stages of disease or even as chemoprevention.

### CONCLUSIONS AND PERSPECTIVES

Vitamin D and its analogs exhibit strong antiproliferative and prodifferentiating effects on different normal and malignant cell types. Several vitamin D analogs have been approved for treating psoriasis, osteoporosis, and secondary hyperparathyroidism and are often used as first or second-line treatment option. Despite promising in vitro as well as in vivo results in various cancer models, vitamin D analog treatment in clinical trials with cancer patients failed to prove efficacy in most trials. Different combinations of analogs and standard cancer therapies should be further explored as well as the correct duration and timing of administration. To unravel the exact working mechanisms of vitamin D analogs more research studies should compare the effects of vitamin D analogs in different cell types to the mother compound.
Furthermore, differences between 1,25(OH)2D3 and its analogs are probably more due to their differences in metabolism and coactivator recruitment than from different genetic regulations. However, some fields such as epigenetics and proteomics remain largely unexplored in comparing the potentially distinctive effects of 1,25(OH)2D3 and its analogs. Since all current genomic and transcriptomic studies focus on established human cell lines, micro-array, and ChIP techniques comparing the effects of 1,25(OH)2D3 and its analogs on human primary tumor tissues should be investigated in the future.

ACKNOWLEDGMENTS

This work was supported by grants from the Fund for Scientific Research (G.0587.09; G.0A17.14N) and the KU Leuven (GOA/14/010).

REFERENCES

Abe, J., Nakano, T., Nishii, Y., Matsumoto, T., Ogata, E., and Ikeda, K. (1991). A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 129, 832–837. doi: 10.1210/en-129-2-832

Akhter, J., Chen, X., Bowrey, P., Bolton, E. J., and Morris, D. L. (1997). Vitamin D3 analog, EB1089, inhibits growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in a nude mouse model. Dis. Colon Rectum 40, 317–321. doi: 10.1016/S0012-010X(97)00117-0

Albert, D. M., Kumar, A., Strugnell, S. A., Darjatmoko, S. R., Lokken, J. M., Bae, S., Y alamarti, B., Ke, Q., Choudhury, S., Yu, H., Karumanchi, S. A., et al. (2006). Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am. J. Kidney Dis. 43, 877–890. doi: 10.1053/j.ajkd.2004.01.012

Colston, K., Colston, M. J., and Feldman, D. (1981). 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 108, 1083–1086. doi: 10.1210/endo-108-3-1083

Coyne, D., Acharya, M., Qiu, P., Abboud, H., Batlle, D., Rosansky, S., et al. (2006). Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am. J. Kidney Dis. 47, 263–276. doi: 10.1053/j.ajkd.2005.10.007

Dahloff, K., Dancey, J., Astrup, L., Skovgaard, T., Hamberg, K. J., Lofs, F. J., et al. (2003). A phase II study of the vitamin D analog Seocalcitol in patients with inoperable hepatocellular carcinoma. Br. J. Cancer 89, 252–257. doi: 10.1038/sj.bjc.6601104

Danielsson, C., Nayeri, S., Wiesinger, H., Thieroff-Ekerdt, R., and Carlberg, C. (1996). Potent gene regulatory and antiproliferative activities of 20-methyl analogues of 1,25 dihydroxyvitamin D3. J. Cell. Biochem. 63, 199–206. doi: 10.1002/sic.19961011632<199::AID-JCB1>3.0.CO;2-T

Dilworth, F. J., Williams, G. R., Kissmeyer, A. M., Nielsen, J. L., Binderup, E., Calverley, M. J., et al. (1997). The vitamin D analog, KH1060, is rapidly converted to both in vivo and in vitro via several pathways: principal metabolites generated retain significant biological activity. Endocrinology 138, 5485–5496. doi: 10.1210/endo.138.12.5485

Ding, N., Yu, R. T., Subramaniam, N., Sherman, M. H., Wilson, C., Rao, R., et al. (2013). A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell 153, 601–613. doi: 10.1016/j.cell.2013.03.028

Eelen, G., Gysemans, C., Verlinden, L., Vanoirbeek, E., De Clercq, P., Van Haver, D., et al. (2007). Mechanism and potential of the growth-inhibitory actions of vitamin D and ana-logs. Curr. Med. Chem. 14, 1893–1910. doi: 10.2174/092986707781058823

Eelen, G., Valle, N., Sato, Y., Rochel, N., Verlinden, L., De Clercq, P., et al. (2008). Supergonistic fluorescent vitamin D3 analogs stabilize helix 12 of the vitamin D receptor. Chem. Biol. 15, 1029–1034. doi: 10.1016/j.chembiol.2008.08.008

Eelen, G., Verlinden, L., Rochel, N., Claessens, F., De Clercq, P., Vandewalle, M., et al. (2005). Supergonistic action of 14-epi-analogs of 1,25-dihydroxyvitamin D explained by vitamin D receptor-coactivator interaction. Mol. Pharmacol. 67, 1566–1573. doi: 10.1124/mol.104.008730

El Abdaimi, K., Dion, N., Papavasiliou, V., Cardinal, P. E., Binderup, L., Goltzman, D., et al. (2000). The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res. 60, 4412–4418.

El Ansari, R., Colston, K. W., Lofs, F. J., Cunningham, D., Anthony, D. A., Gogas, H., et al. (2002). A phase II trial of the vitamin D analogue Seocalcitrol (EB1089) in patients with inoperable pancreatic cancer. Br. J. Cancer 86, 680–685. doi: 10.1038/sj.bjc.6600162

Fichera, A., Little, N., Dougherty, U., Mustafi, R., Cerda, S., Li, Y. C., et al. (2007). A vitamin D analogue inhibits colorectal cancer and high grade pin. Prostate 73, 970–978. doi: 10.1002/pro.2264

Ghous, Z., Akhter, I., Pourgholami, M. H., and Morris, D. L. (2008). Inhibition of hepatocellular cancer by EB1089: in vitro and in vivo study. Anticancer Res. 28, 3757–3761.

Gonzalez-Pardo, V., Martin, D., Gutkind, J. S., Verstuyf, A., Bosshard, R., de Boland, A. R., et al. (2010). A vitamin D analog inhibit the growth of endothelial cells transformed by Kaposi sarcoma-associated herpes virus G protein-coupled receptor in vitro and in vivo. Endocrinology 151, 23–31. doi: 10.1210/en.2009-0650

Griffin, M. D., Xing, N., and Kumar, R. (2004). Gene expression profiles in dendritic cells conditioned by 1,25-dihydroxyvitamin D3 analog. www.frontiersin.org
Kawa, S., Yoshizawa, K., Nikaido, T., and Kiyosawa, K. (2005). Inhibitory effect of 22-oxa-1,25-dihydroxyvitamin D3 on the prolif-eration of pancreatic cancer cell lines. *J. Steroid Biochem. Mol. Biol.*, 97, 173–177. doi:10.1016/j.jbmb.2005.06.021

Kawa, S., Yoshizawa, K., Toko, M., Imai, H., Oguchi, H., Kiyosawa, K., et al. (1996). Inhibitory effect of 22-oxa-1,25-dihydroxyvitamin D3 on the prolif-eration of pancreatic cancer cell lines. *Gastroenterology* 110, 1605–1613. doi:10.1053/gast.1996.v110.pm813068

Kissmeyer, A. M., Binderup, E., Binderup, L., Mork Hansen, C., Andersen, N. R., Makin, H. L., et al. (1997). Metabolism of the vitamin D analogue EB 1089: identification of in vivo and in vitro liver metabolites and their biological activities. *Biochem. Pharmacol.*, 53, 1087–1097. doi:10.1016/S0006-2952(96)00816-7

Kriebitzsch, C., Verlinden, L., Eelen, G., Tan, B. K., Van Camp, M., Bouillon, R., et al. (2009). The impact of 1,25(OH)2D3 and its structural analogs on gene expression in cancer cells—a microarray approach. *Anticancer Res.*, 29, 3471–3483.

Lambert, J. R., Eddy, V. J., Young, C. D., Persons, K. S., Sarkar, S., Kelly, J. A., et al. (2010). A vitamin D receptor-alkylating derivative of 1alpha,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growth. *Cancer Prev. Res. (Phila.)* 3, 1596–1607. doi:10.1158/1940-6207.CAPR-10-0122

Lawrence, J. A., Akman, S. A., Melin, S. A., Case, L. D. and Schwartz, G. G. (2013). Oral paricalcitol (19-nor-1,25-dihydroxyvitamin D2) in women receiv-ing chemotherapy for metastatic breast cancer: a feasibility trial. *Cancer Biol. Ther.*, 14, 476–480. doi:10.4161/cbt.24350

Lee, H. J., Paul, S., Atalla, N., Thomas, P. E., Lin, X., Yang, L., et al. (2008). Gemini vitamin D analogues inhibit estrogen receptor-positive and estrogen receptor-negative mammary tumorigenesis without hypercalcemic toxicity. *Cancer Prev. Res. (Phila.)* 1, 476–484. doi:10.1158/1940-6207.CAPR-08-0084

Lee, H. J., So, J. Y., DeCastro, A., Smolarek, A., Paul, S., Maehr, H., et al. (2010). Gemini vitamin D analogue suppresses ErbB2-positive mammary tumor growth via inhibition of ErbB2/ATK/ERK signaling. *J. Steroid Biochem. Mol. Biol.*, 121, 408–412. doi:10.1016/j.jsbmb.2010.03.053

Lin, R., Nagai, Y., Sladek, R., Bastian, Y., Ito, J., Petrecca, K., et al. (2002). Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. *Mol. Endocrinol.*, 16, 1243–1256. doi:10.1210/mend.16.6.0874

Liska, J., Macejova, D., Ondikova, S., and Britko, J. (2012). Morphology of 1-methyl-1-nitrosourea induced rat mammary tumours after treatment with precursor of pythacemic acid or its combination with vitamin D analogue. *Endocr. Regul.* 46, 21–26. doi:10.4149/endr_2012_021

Liu, G., Oettel, K., Ripple, G., Staab, M. J., Horvath, D., Alberti, D., et al. (2002). Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer. *Clin. Cancer Res.*, 8, 2820–2827.

Liu, G., Wilding, G., Staab, M. J., Horvath, D., Miller, K., Dresen, A., et al. (2003). Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer. *Clin. Cancer Res.*, 9, 4077–4083.

Liu, Y. Y., Nguyen, C., Ali Gardezi, S. A., Schnirer, I., and Peleg, S. (2001). Differential regulation of heterodimerization by 1alpha,25-dihydroxyvitamin D3 and its 20-epi analog. *Steroids* 66, 203–212. doi:10.1016/S0039-128X(00)00151-3

Liu, Y. Y., Nguyen, C., and Peleg, S. (2000). Regulation of ligand-induced heterodimerization and coactivator interaction by the activation function-2 domain of the vitamin D receptor. *Mol. Endocrinol.*, 14, 1776–1787. doi:10.1210/mend.14.11.0560

Lokeshwar, B. L., Schwartz, G. G., Selzer, M. G., Burnstein, K. L., Zhuang, S. H., Block, N. L., et al. (1999). Inhibition of prostate cancer metastasis in vivo: a comparison of 1,25-dihydroxyvitamin D (calcitriol) and EB1089. *Cancer Epidemiol. Biomarkers Prev.*, 8, 241–248.

Lundqvist, J., Hansen, S. K., and Lykkefeldt, A. E. (2013). Vitamin D analogue EB1089 inhibits aromatase expression by dissociation of coomodulator WSTF from the CYP19A1 promoter—a new regulatory pathway for aromatase. *Biochim. Biophys. Acta* 1833, 40–47. doi:10.1016/j.bbamcr.2012.10.012

Ma, Y., Yu, W. D., Hidalgo, A. A., Luo, W., Delansorne, R., Cusack, S. et al. (2013). Inecalciol, an analog of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system. *Cell Cycle* 12, 743–752. doi:10.4161/cc.23846

Macejova, D., Ondikova, S., Jakubikova, L., Mylnarcikova, A., Scsoukova, S., Liska, J., et al. (2011). MNU-induced mammary gland carcinogenesis: chemopre-ventive and therapeutic effects of vitamin D and Seocalcitol on selected regulatory vitamin D receptor pathways. *Toxicol. Lett.*, 207, 60–72. doi:10.1016/j.toxlet.2011.07.029

Matsumoto, T., Ito, M., Hayashi, Y., Hirota, T., Tanigawara, Y., Sone, T., et al. (2011). A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures—a randomized, active comparator, double-blind study. *Bone* 49, 605–612. doi:10.1016/j.bone.2011.07.011

Milczarek, M., Pourski, M., Kuttner, A., and Wietrzyk, J. (2013). Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer model. *BMC Cancer* 13:294. doi:10.1186/1471-2407-13-294
with the vitamin D3 analog, EB1089. *Endocrinology* 139, 2102–2110. doi: 10.1210/en.139.4.2102

Vegezna, V., O’Kelly, J., Said, J., Uskokovic, M., Binderup, L., and Koeffle, H. P. (2003). Ability of potent vitamin D3 analogs to inhibit growth of prostate cancer cells in vivo. *Anticancer Res.* 23, 283–289.

Wietrzyk, J., Nevovzhay, D., Filip, B., Milczarek, M., and Kutner, A. (2007). The antitumor effect of lowered doses of cytostatics combined with new analogs of vitamin D in mice. *Anticancer Res.* 27, 3387–3398.

Wietrzyk, J., Nevovzhay, D., Milczarek, M., Filip, B., and Kutner, A. (2008). Toxicity and antitumor activity of the vitamin D3 analogs PRI-1906 and PRI-1907 in combined treatment with cyclophosphamide in a mouse mammary cancer model. *Cancer Chemother. Pharmacol.* 62, 787–797. doi: 10.1007/s00280-007-0666-6

Wietrzyk, J., Pelczynska, M., Madej, J., Dzimira, S., Kusnierczyk, H., Kutner, A., et al. (2004). Toxicity and antineoplastic effect of (24R)-1,24-dihydroxyvitamin D3 (PRI-2191). *Steroids* 69, 629–635. doi: 10.1016/j.steroids.2004.05.015

Wu-Wong, J. R., Nakane, M., Ma, J., Ruan, X., and Kroeger, P. E. (2007). VDR-mediated gene expression patterns in resting human coronary artery smooth muscle cells. *J. Cell. Biochem.* 100, 1395–1405. doi: 10.1002/jcb.21133

Yamamoto, H., Shevde, N. K., Warrier, A., Plum, L. A., DeLuca, H. F., and Pike, J. W. (2003). 2-Methylene-19-nor-20(S)-1,25-dihydroxyvitamin D3 potently stimulates gene-specific DNA binding of the vitamin D receptor in osteoblasts. *J. Biol. Chem.* 278, 31756–31765. doi: 10.1074/jbc.M304737200

Yoon, J. S., Kim, J. Y., Park, H. K., Kim, E. S., Ahn, K. S., Yoon, S. S., et al. (2008). Antileukemic effect of a synthetic vitamin D3 analog, HY-11, with low potential to cause hypercalcemia. *Int. J. Oncol.* 32, 387–396. doi: 10.3892/ijo.32.2.387

Zella, L. A., Meyer, M. B., Nerenz, R. D., and Pike, J. W. (2009). The enhanced hypercalcemic response to 20-epi-1,25-dihydroxyvitamin D3 results from a selective and prolonged induction of intestinal calcium-regulating genes. *Endocrinology* 150, 3448–3456. doi: 10.1210/en.2009-0113

Zhang, X., Jiang, E., Li, P., Li, C., Ma, Q., Nicosia, S. V., et al. (2005). Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089. *Clin. Cancer Res.* 11, 323–328.

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 06 February 2014; paper pending published: 19 February 2014; accepted: 13 March 2014; published online: 03 April 2014.

Citation: Leyssens C, Verlinden L and V erstuyf A (2014) The future of vitamin D analogs. Front. Physiol. 5:122. doi: 10.3389/fphys.2014.00122

This article was submitted to Integrative Physiology, a section of the journal Frontiers in Physiology.

Copyright © 2014 Leyssens, Verlinden and Verstuyf. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.